The purpose of this study is to determine treatment efficacy and tolerability of second-line treatment in patients with small cell lung cancer comparing oral combinaison chemotherapy with intravenous combination chemotherapy.

Determined treatment efficacy and tolerability of second-line treatment in patients with small cell lung cancer comparing oral combinaison chemotherapy with intravenous combination chemotherapy.

Inclusion Criteria:

• Small-cell lung cancer.
• Patients who, after (at least) a first line of chemotherapy based on platinum, had a partial response and then progressed, or who had a complete response and then relapsed within three months following the last course of this first-line therapy.
• Measurable or assessable disease.
• Life expectancy >2 months.
• Patients with a therapeutic risk level of <5 points (see section 6: "Treatment flowchart").
• Age >18 years;
• Performance status (WHO) <2;
• One measurable target lesion in a non irradiated region;
• Prior radiotherapy authorized unless it targeted the only measurable lesion;
• Biological criteria: WBC >2000/mm3, PMN >1500/mm3, platelets >100 000/mm3, creatinemia <2 x ULN, bilirubinemia \

Patients with Small-cell lung cancer who, after (at least) a first line of chemotherapy based on platinum, had a partial response and then progressed, or who had a complete response and then relapsed within three months following the last course of this first-line therapy.